(Q63817702)
Statements
A Phase III Randomized, Open-Label, Multicenter Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray Formulations in Elderly Patients (≥ 75 Years Old) With Nocturia (English)
0 references
April 2010
0 references
November 2010
0 references
32
0 references
75 year
0 references
95 year
0 references